Loading…
← CockpitCompetitor Analysis › ARQT Arcutis Biotherapeutics IncOpen in the cockpit ↗

Arcutis Biotherapeutics IncARQTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Dermatology pharma selling Zoryve, a topical treatment for psoriasis, eczema and seborrheic dermatitis.

Momentum strong 78
Mkt cap
$3.49B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$64.1M
20-day average traded
Fwd P/E
41.0×
forward earnings
ROIC−WACC
+12.6 pp
WACC 13.1%
Hurdle
-318 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$27.61
1D+1.0%
1W-2.7%
1M-15.9%
3M+8.9%
6M+34.9%
YTD-4.9%
1Y+5.5%
ATR %5.7%
Beta1.47
52w lowhigh20.7% off high

What Arcutis Biotherapeutics does

Dermatology pharma selling Zoryve, a topical treatment for psoriasis, eczema and seborrheic dermatitis.

Rests almost entirely on Zoryve, sold in the US through wholesalers and pharmacies and paid for by insurers and pharmacy-benefit managers, the intermediaries that decide how easily patients can get it. Sales therefore depend on insurance coverage and on persuading doctors to prescribe a newer topical drug.

Products and services

  • Zoryve cream/foam (roflumilast)
  • Pipeline dermatology assets

Customers

  • Dermatologists
  • Pediatricians (for eczema)

Where it sits in the supply chain

  • Dermatology pharmaceuticals
  • Topical drug commercialization
  • Specialty dermatology sales

What could go right

  • Zoryve label expansion and volume growth
  • Payer coverage improvements

What could go wrong

  • Reimbursement/access hurdles
  • Competition from steroid and JAK topicals

Moat: narrow (IP / patents). Zoryve's steroid-free mechanism and patents differentiate it from generic topical steroids.

Headquarters: Westlake Village, California, US · Founded: 2016 · Employees: 354

Named competitors

Arcutis Biotherapeutics at a glance

Size Arcutis Biotherapeutics (ARQT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.49B, the 1435th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.61 on 18 Nov 2026.

Performance Over six months the shares gained 34.9%, against +3.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 60.0% over the last twelve months (peer median +7.9%); the operating margin is 6.9% (peer median 12.2%).

Valuation It trades at 41.0× forward earnings against a peer median of 16.8× (3rd most expensive of 12).

Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +367%, so the hurdle is -318 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 12.6 points above its cost of capital (13.1% WACC).

Short interest Short interest is 14.4% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026ARQT 131Peer median 105
Six months, rebased to 100: Arcutis Biotherapeutics against the median of its 20 peers (local-currency closes).

Arcutis Biotherapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$509M$376M$197M$59.6M$3.69M
Revenue growth—+91%+230%+1,517%—
Gross profit$464M$339M$177M$53.5M$1.99M
EBITDA$38.1M-$6.86M-$126M-$239M-$300M
Net income$29.9M-$16.1M-$140M-$262M-$311M
Free cash flow$59.7M-$6.31M-$112M-$247M-$258M
Capital expenditure$255,000$10.7M$5.14M$428,000$7.83M
Total debt$124M$114M$111M$206M$203M

Quarterly statements and history in the cockpit →

Arcutis Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%1877ACUTAAS002262SFZNWOCKPHARMAAMLXVRDN2096PPLPHARMA600521000739OGNSLSXENE1513ARQT6-month return →1-month return →
Up and to the right = strong over both horizons. Arcutis Biotherapeutics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×150×ACUTAAS002262SFZN2096PPLPHARMA3320000739OGN1513600511ARQTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Arcutis Biotherapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%002262WOCKPHARMA2096TARSARQTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Arcutis Biotherapeutics is the large dot.

Arcutis Biotherapeutics competitors and peer comparison

Head to head with its named competitors (ARQT vs INCY vs PFE vs OGN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Arcutis Biotherapeutics ARQT$3.49B+35%+60%7%41.0×49.2%
Incyte INCY$24.0B+21%+25%12%15.1×14.2%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Organon & OGN$3.66B+3%-3%20%4.0×-4.1%
Galderma GALD.SW$51.9B+18%+16%19%45.7×18.0%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%

How Arcutis Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Arcutis Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureARQTPeer medianRank in peer set
1-month return-15.9%+4.5%2nd lowest of 21
6-month return+34.9%+3.4%6th highest of 20
Distance from 52-week high-20.7%-20.9%11th highest of 21
Revenue growth (TTM)+60.0%+7.9%3rd highest of 18
Operating margin6.9%12.2%7th lowest of 16
Forward P/E41.0×16.8×3rd most expensive of 12
Growth the price implies (Req g, 7 yrs)49.2%-2.8%2nd most demanding of 11
Growth delivered (Del g)+367.3%+5.6%highest of 11
Hurdle (Req g minus delivered)-318.1 pp-10.8 ppleast demanding of 11
ROIC minus cost of capital+12.6 pp+3.7 pp3rd highest of 16
EV / EBITDA88.0×12.1×most expensive of 8
Net debt / EBITDA-3.6×2.6×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%

Questions

Who are Arcutis Biotherapeutics's main competitors?
Named competitors: Incyte (Opzelura) (INCY), LEO Pharma (private or unlisted), Pfizer (Eucrisa) (PFE), Dermavant Sciences (private or unlisted), Organon (OGN), Galderma (GALD.SW). The cockpit's measured peer set (industry) also includes Shanghai Junshi Biosciences (1877.HK), Acutaas Chemicals (ACUTAAS.NS), Jiangsu Nhwa Pharmaceutical (002262.SZ), Siegfried (SFZN.SW), Parabilis Medicines (PBLS), Wockhardt (WOCKPHARMA.NS).
Is Arcutis Biotherapeutics expensive compared with its peers?
On forward p/e it trades at 41.0× against a peer median of 16.8×, 3rd most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +367%, so the hurdle is -318 pp: the price already allows for a slowdown.
How has Arcutis Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +34.9% against +3.4% for the median peer; over one year +5.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.